Drugline is a fortnightly electronic drug bulletin for health professionals.
Scroll

Drugline

Drugline is a fortnightly electronic drug bulletin providing information on new medicines, new developments, current affairs, new indications, new PBS listings and deletions and general issues of importance to all health professionals. Click below to view the most recent volumes of Drugline.

Expanded PBS Listing for Dapagliflozin

Drugline Volume 493

The Pharmaceutical Benefits Scheme (PBS) listing for dapagliflozin has recently been expanded. It is now subsidised for the treatment of heart failure independent of left ventricular ejection fraction (LVEF). When used for the management…

Read more

Cephalosporin-induced Neurotoxicity

Drugline Volume 492

The product information documents of many cephalosporin products have recently been updated to include warnings of neurotoxicity. Cephalosporins are broad-spectrum beta-lactam antibiotics that are commonly used to treat a range of infections. Neurotoxicity has…

Read more

Tebentafusp for Uveal Melanoma

Drugline Volume 491

Tebentafusp is now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of advanced uveal melanoma. Uveal melanoma is a rare cancer originating from melanocytes in the choroid, iris, or ciliary body of…

Read more
prescription

Subcutaneous Natalizumab on the PBS

Drugline Volume 490

The subcutaneous form of natalizumab is now available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of relapsing-remitting multiple sclerosis. Natalizumab is a monoclonal antibody that binds to α4 integrins on leucocytes. This…

Read more

Melanoma Therapy Added to the PBS

Drugline Volume 489

From 1 February 2024, Opdualag® will be available on the Pharmaceutical Benefits Scheme (PBS) for the treatment of advanced melanoma. Opdualag® is a combination of two immune checkpoint inhibitors, nivolumab and relatlimab. Nivolumab inhibits…

Read more

Expanded PBS Listing for Orkambi®

Drugline Volume 488

The Pharmaceutical Benefits Scheme (PBS) listing for lumacaftor plus ivacaftor (Orkambi®) has recently been expanded to include patients from one year of age. This medicine is indicated for the treatment of cystic fibrosis in…

Read more
Load More